When a baby or young child undergoes a bone marrow transplant (BMT) to treat severe combined immunodeficiency (SCID), the treatment may resolve the condition; however, it can also lead to health problems years afterward. In a recent SCID Compass Lunch & Learn, Dr. Ami Shah, clinical professor of pediatrics at Stanford University and pediatric
Read MoreParents of children with severe combined immunodeficiency (SCID) exhibit resiliency as they learn to overcome the stress associated with a life-threatening diagnosis. They rely heavily on support from healthcare providers, family, friends, and parents in the SCID community and demonstrate their own ability to create coping strategies. Such is
Read MoreParents of children with adenosine deaminase (ADA) deficient severe combined immunodeficiency (SCID) learned that after several years of delay, clinical trials to treat ADA-SCID using gene therapy will resume in 2023. Dr. Donald Kohn, University of California Los Angeles (UCLA) Department of Microbiology, Immunology, and Molecular Genetics
Read MoreSome children with severe combined immunodeficiency (SCID) who are treated with bone marrow transplant (BMT) require immunoglobulin infusions for months, sometimes years, after the transplant. But why? And what can parents expect as their child recovers from the transplant and builds a new immune system from donor cells? Dr. Manish Butte Two
Read MoreUpdated - Watch “Gene Therapy Updates for ADA-SCID” now. Parents of children with adenosine deaminase severe combined immunodeficiency (ADA-SCID) anxiously await the restart of gene therapy clinical trials at the University of California of Los Angeles (UCLA), and an upcoming SCID Compass Lunch & Learn offers them an update. During the
Read More
